Peptide News Digest

#State-Regulation

1 story

Regulatory · View digest

Kentucky Board of Pharmacy Bars Compounding of BPC-157, TB-500, and Four Other Peptides Despite the HHS Enforcement Policy

The Kentucky Board of Pharmacy voted on November 18 to enforce its compounding rule as written and to refuse waivers for BPC-157, TB-500, Epitalon, Semax, KPV, and MOTS-c, the six peptides covered by HHS's October 30 enforcement discretion policy. In a November 19 compliance alert, the board said none of the six has a USP or National Formulary monograph, is part of an FDA-approved drug, or is on FDA's 503A bulks list, so compounding them in or into Kentucky "has never been authorized." In-state and out-of-state pharmacies must not compound, dispense, or ship them to Kentucky patients, and violations can cost a pharmacy its license or bring a fine. The board said it will notify licensees if FDA adds any of the six to its bulks list.